MAIA Biotechnology (MAIA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
22 May, 2026Opening remarks and agenda
Meeting called to order and chaired by Vlad Vitoc, welcoming shareholders and outlining virtual voting procedures.
Business portion conducted first, followed by a Q&A session at the end.
Board and executive committee updates
Attendance included independent board members, executive management, legal counsel, accountants, and representatives from Broadridge Financial Solutions.
Adelina Louie Ngar Yee (Audit and Nominating/Corporate Governance Chair) and Stan V. Smith (Compensation Chair) highlighted.
Shareholder proposals
Election of Adelina Louie Ngar Yee and Steven M. Chaouki as Class I directors for a three-year term proposed and nominated.
Ratification of Grant Thornton LLP as independent auditors for fiscal year ending December 31, 2026, proposed.
Latest events from MAIA Biotechnology
- Disclosure updates compensation to the CEO's brother and confirms proxy voting procedures.MAIA
Proxy filing19 May 2026 - $33M equity raise boosts cash to $34.4M, funding Phase 3 NSCLC trial; net loss rises to $6.37M.MAIA
Q1 202611 May 2026 - Proxy statement amended to disclose equity compensation plan details and available shares.MAIA
Proxy filing27 Apr 2026 - Election of directors and auditor ratification headline the 2026 virtual annual meeting.MAIA
Proxy filing7 Apr 2026 - Virtual meeting to elect directors and ratify auditor, with strong governance and director alignment.MAIA
Proxy filing7 Apr 2026 - Advanced clinical pipeline and $33M capital raise position company for pivotal 2026 milestones.MAIA
Q4 202523 Mar 2026 - THIO's pivotal trials show high efficacy in cancer, with major milestones and approvals expected by 2026.MAIA
Biotech Showcase 2025 Investor Conference10 Jan 2026 - Key votes include director elections, auditor ratification, and a major share authorization increase.MAIA
Proxy Filing2 Dec 2025 - Shareholders will vote on director elections, auditor ratification, and doubling authorized shares.MAIA
Proxy Filing2 Dec 2025